BioDelivery Sciences International Revenue and Competitors
Estimated Revenue & Valuation
- BioDelivery Sciences International's estimated annual revenue is currently $165.7M per year.
- BioDelivery Sciences International received $50.0M in venture funding in May 2018.
- BioDelivery Sciences International's estimated revenue per employee is $767,222
- BioDelivery Sciences International's total funding is $250.7M.
- BioDelivery Sciences International's current valuation is $302.3M. (January 2022)
Employee Data
- BioDelivery Sciences International has 216 Employees.
- BioDelivery Sciences International grew their employee count by 14% last year.
BioDelivery Sciences International Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $2.1M | 25 | -7% | N/A | N/A |
#2 | $3.2M | 16 | 0% | N/A | N/A |
#3 | $67.1M | 334 | 6% | N/A | N/A |
#4 | $25.5M | 127 | 55% | N/A | N/A |
#5 | $72.6M | 289 | 28% | $35M | N/A |
#6 | $3.3M | 40 | 48% | N/A | N/A |
#7 | $3.1M | 38 | -25% | N/A | N/A |
#8 | $165.7M | 216 | 14% | $250.7M | N/A |
#9 | $22.3M | 111 | 4% | $637.8K | N/A |
#10 | $44M | 219 | 8% | N/A | N/A |
What Is BioDelivery Sciences International?
BioDelivery Sciences ("BDSI"®) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. We are utilizing our novel and proprietary BioErodible MucoAdhesive (BEMA®) and other drug delivery technologies to develop and commercialize, either on our own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$250.7M
Total Funding
216
Number of Employees
$165.7M
Revenue (est)
14%
Employee Growth %
$302.3M
Valuation
N/A
Accelerator
BioDelivery Sciences International News
BioDelivery Sciences International (NASDAQ:BDSI) Coverage Initiated by Analysts at StockNews.com. Posted by admin on Apr 25th, 2022.
Northland Securities cut BioDelivery Sciences International from an outperform rating to a market perform rating in a research note on...
Brokerages Set BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Target Price at $5.93. Posted by admin on Apr 11th, 2022.
08, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty ...
Other Companies in Raleigh
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $50.4M | 218 | 16% | N/A |
#2 | $15M | 218 | 6% | N/A |
#3 | $33.7M | 219 | 0% | N/A |
#4 | $15M | 220 | -3% | N/A |
#5 | $61.2M | 220 | 8% | N/A |
BioDelivery Sciences International Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2002-07-09 | $9.4M | Public Offering | Article | |
| 2005-07-19 | $7.0M | Undisclosed | Clinical Development Capital L | Article |
| 2005-08-05 | $7.0M | Undisclosed | Article | |
| 2006-02-17 | $7.0M | Undisclosed | CDC IV LLC | Article |
| 2012-11-29 | $40.0M | Undisclosed | William Blair & Company L L C | Article |
| 2014-02-11 | $60.0M | Undisclosed | Article | |
| 2015-06-02 | $20.7M | Undisclosed | MidCap Financial | Article |
| 2017-02-24 | $75.0M | Undisclosed | CRG LP, | Article |
| 2018-05-18 | $50.0M | Undisclosed | William Blair & Company, L.L.C. | Article |
